NCT06338397 · RECRUITING

Social & Affective Cognition in Alzheimer's Disease & Associated Disorders

This study is testing a tool called SCANN to measure how well people with Alzheimer's disease or frontotemporal degeneration understand social cues and emotions — things like reading a room, making decisions around others, or recognizing vulnerability. Researchers want to see whether those social and emotional abilities connect to real-world behavior problems. This is a Phase NA observational pilot study, meaning it is exploratory research, not a treatment trial.

You may qualify if

  • Men and women;
  • 40 to 85 years of age (included);
  • Registered with the French Social Security;
  • Have a study partner. The study partner is required to complete several scales. If the subjects or their study partners are not able to drive, their transport fees will be reimbursed by the promotor.
  • Fluent in French, able to read and write;

You're excluded if

  • Participants who have contraindications to perform an MRI scan;
  • Participants with significant sensory deficits that are not corrected by suitable devices.
  • Participants with dementia caused by a non-neurodegenerative disease, including patients with severe cerebrovascular risk factor load, in the judgment of the investigator;
  • Participants with other neurodegenerative disease such as Lewy body dementia and Parkinson's disease;
  • Participants with other serious neurological disorder such as brain tumor, stroke, epilepsy, hydrocephalus and any condition which contraindicates, in the investigator's judgment, entry to the study;
  • Participants with excessive alcohol intake or drug abuse, in the judgment of the investigator;
  • Participants who, in the opinion of the investigator, have a risk of non-compliance to the study procedures;

The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.

Eligibility criteria as of 2026-04-30

View full record on ClinicalTrials.gov

All APOE4 clinical trials